Alterations in the common pathway of coagulation during weight loss induced by gastric bypass in severely obese patients

Obesity

Volumn 20, Issue 5, 2012, Pages 1048-1056

  Pardina, Eva ^a   Ferrer, Roser ^b   Rivero, Joaquín ^c   Baena Fustegueras, Juan A ^d   Lecube, Albert ^b   Fort, Jose M ^b   Vargas, Víctor ^e   Catalán, Roberto ^b   Peinado Onsurbe, Julia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER; MALE; NORMAL VALUE; OBESITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; STOMACH BYPASS; THERAPY EFFECT; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ANTITHROMBIN III; BLOOD COAGULATION; FEMALE; FIBRINOGEN; GASTRIC BYPASS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY, MORBID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; WEIGHT LOSS;

EID: 84860299075     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.361     Document Type: Article

References (32)

1. Luyendyk JP, Mattes WB, Burgoon LD et al. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 2004;80:203-213.
2. Quax PH, van den Hoogen CM, Verheijen JH et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990;265:15560-15563.
3. Lagoa CE, Vodovotz Y, Stolz DB et al. The role of hepatic type 1plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock. Hepatology 2005;42:390-399.
4. Kruithof EK. Plasminogen activator inhibitors-A review. Enzyme 1988;40:113-121.
5. Rajala MW, Scherer PE. Minireview: The adipocyte-At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-3773.
6. Kohler HP, Grant PJ. Plasminogen-Activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
7. Alessi MC, Bastelica D, Mavri A et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268.
8. Patnaik MM, Moll S. Inherited antithrombin deficiency: A review. Haemophilia 2008;14:1229-1239.
9. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009;10:554-563.
10. Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler Thromb Vasc Biol 1996;16:499-503.
11. Chen SB, Lee YC, Ser KH et al. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obes Surg 2009;19:461-466.
12. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA 2001;285:2486-2497.
13. Standardization of anthropometric measurements: The Airlie (VA) Consensus Conference. Human Kinetics Publishers: Champaign, 1988.
14. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. Br J Nutr 1991;65:105-114.
15. Bonora E, Micciolo R, Ghiatas AA et al. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Metab Clin Exp 1995;44:1617-1625.
16. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
17. Leahy JL, Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 1990;126:1593-1598.
18. Lindeman JH, Pijl H, Toet K et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond) 2007;31:1671-1679.
19. Skurk T, Hauner H. Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-1364.
20. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441-1443.
21. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liver. Thromb Haemost 2008;100:992-1006.
22. Aso Y, Matsumoto S, Fujiwara Y et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metab Clin Exp 2002;51:471-476.
23. Solá E, Vayá A, Simó M et al. Fibrinogen, plasma viscosity and blood viscosity in obesity. Relationship with insulin resistance. Clin Hemorheol Microcirc 2007;37:309-318.
24. Jensen L, Sloth B, Krog-Mikkelsen I et al. A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women. Am J Clin Nutr 2008;87:97-105.
25. Herishanu Y, Rogowski O, Polliack A, Marilus R. Leukocytosis in obese individuals: Possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006;76:516-520.
26. Pardina E, Ferrer R, Baena-Fustegueras JA et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg 2010;20:623-632.
27. Kopp HP, Krzyzanowska K, Möhlig M et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond)2005;29:766-771.
28. Taniguchi A, Fukushima M, Seino Y et al. Platelet count is independently associated with insulin resistance in non-obese Japanese type 2 diabetic patients. Metab Clin Exp 2003;52:1246-1249.
29. Shim WS, Kim HJ, Kang ES et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabetes Res Clin Pract 2006;73:284-291.
30. Dixon JB, O'Brien PE. Obesity and the white blood cell count: Changes with sustained weight loss. Obes Surg 2006;16:251-257.
31. Anfossi G, Mularoni EM, Burzacca S et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998;21:121-126.
32. Corsonello A, Corica F. Leptin, obesity and platelet responsiveness: Another piece in the puzzle. Thromb Haemost 2008;100:960-961.